Brain Metastases Clinical Trial
Official title:
Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of CNS Metastases
Stereotactic radiation therapy is an important and common method of treating brain metastases in patients with malignant disease. Today, however, there are no methods available to determine the metastasis' radiation sensitivity in advance and treatment responses can only be seen by changing of the size of the metastasis on conventional X-ray examinations, computed tomography (CT) and magnetic resonance imaging (MRI). Changes in the size of the metastases is something that is often seen weeks / months after treatment is completed. At Lund University Hospital, a new imaging technique, diffusional variance decomposition (DIVIDE), has now been developed. With this technique, the scatter in isotropic and anisotropic diffusion can be measured for each measuring point, which provides significantly more information about the properties of the tissue compared to current methods.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients prescribed stereotactic radiation therapy to the brain, where MRI imaging is included in the treatment preparations. 2. Cohesive remaining solid tumor component of =10mm. 3. Age =18 years. 4. World Health Organisation (WHO) performance status 0-1. Exclusion Criteria: 1. Inability to decide for oneself on participation in the study. 2. Inability to understand the Swedish language. 3. Metastases close to the base of the skull. 4. Contraindications to conducting an MRI examination. 5. Contraindications to obtaining contrast media during MRI examination. 6. Expected survival less than 6 months. 7. Previous radiation treatment to the same site in the brain, i.e. current treatment is a rope radiation. - |
Country | Name | City | State |
---|---|---|---|
Sweden | Lund University Hospital | Lund |
Lead Sponsor | Collaborator |
---|---|
Lund University Hospital |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Grade of radiation sensitivity to brain metastasis. | Evaluation done by MRI to see whether radiation sensitivity can be measured during radiotherapy and after 3 and 6 months after end of treatment. | Is evaluated after end of radiotherapy, that is after 3 days, as all subjects receive 3x10 Gy. | |
Primary | Grade of radiation sensitivity to brain metastasis. | Evaluation done by MRI to see whether radiation sensitivity can be measured during radiotherapy and after 3 and 6 months after end of treatment. | Is evaluated after 3 months after end of treatment. | |
Primary | Grade of radiation sensitivity to brain metastasis. | Evaluation done by MRI to see whether radiation sensitivity can be measured during radiotherapy and after 3 and 6 months after end of treatment. | Is evaluated after 6 months after end of treatment. | |
Primary | Early changes in the tumor during and after completion of radiation therapy. | Evaluation done by MRI to see whether early changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment. | Is evaluated after end of radiotherapy, that is after 3 days, as all subjects receive 3x10 Gy. | |
Primary | Early changes in the tumor during and after completion of radiation therapy. | Evaluation done by MRI to see whether early changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment. | Is evaluated after 3 months after end of treatment. | |
Primary | Early changes in the tumor during and after completion of radiation therapy. | Evaluation done by MRI to see whether early changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment. | Is evaluated after 6 months after end of treatment. | |
Primary | Changes linked to treatment responses. | Evaluation done by MRI to see whether changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment. | Is evaluated after end of radiotherapy, that is after 3 days, as all subjects receive 3x10 Gy. | |
Primary | Changes linked to treatment responses. | Evaluation done by MRI to see whether changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment. | Is evaluated after 3 months after end of treatment. | |
Primary | Changes linked to treatment responses. | Evaluation done by MRI to see whether changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment. | Is evaluated after 6 months after end of treatment. | |
Primary | Differentiate between radiation damage (radionecrosis) and residual / recurrent tumor. | Evaluation done by MRI to see whether differentiation between radionecrosis and residual/recurrent tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment. | Is evaluated after end of radiotherapy, that is after 3 days, as all subjects receive 3x10 Gy. | |
Primary | Differentiate between radiation damage (radionecrosis) and residual / recurrent tumor. | Evaluation done by MRI to see whether differentiation between radionecrosis and residual/recurrent tumor can be measured during radiotherapy after 3 months after end of treatment. | Is evaluated after 3 months after end of treatment. | |
Primary | Differentiate between radiation damage (radionecrosis) and residual / recurrent tumor. | Evaluation done by MRI to see whether differentiation between radionecrosis and residual/recurrent tumor can be measured during radiotherapy and after and 6 months after end of treatment. | Is evaluated after 6 months after end of treatment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04074096 -
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
|
Phase 2 | |
Recruiting |
NCT04474925 -
Pre- Versus Post-operative SRS for Resectable Brain Metastases
|
Phase 3 | |
Recruiting |
NCT05358340 -
Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions
|
N/A | |
Recruiting |
NCT05559853 -
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
|
||
Completed |
NCT03189381 -
Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases
|
N/A | |
Completed |
NCT02082587 -
Toronto BNB Pilot Study
|
N/A | |
Terminated |
NCT01551680 -
A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases
|
Phase 1 | |
Terminated |
NCT00717275 -
Study of Temozolomide to Treat Newly Diagnosed Brain Metastases
|
Phase 2 | |
Recruiting |
NCT05048212 -
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
|
Phase 2 | |
Recruiting |
NCT03714243 -
Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases
|
N/A | |
Recruiting |
NCT05573815 -
Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images
|
N/A | |
Recruiting |
NCT04899908 -
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
|
Phase 2 | |
Completed |
NCT04507217 -
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
|
Phase 2 | |
Recruiting |
NCT05452005 -
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT06457906 -
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
|
Phase 3 | |
Completed |
NCT04170777 -
Perfexion Registration Using CBCT
|
||
Recruiting |
NCT03027544 -
Tomotherapy for Refractory Brain Metastases
|
N/A | |
Completed |
NCT04178330 -
Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases
|
N/A | |
Terminated |
NCT02187822 -
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
|
Phase 1 | |
Terminated |
NCT00538343 -
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
|
Phase 2 |